News

Through the extended agreement, Kamada secured $26 million in additional revenues of Glassia, the Company’s proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic

Vitavis CEO Tim Tigner said Pruvin supports healthy metabolism resulting in numerous significant benefits to users. "Pruvin supports healthy metabolism resulting in numerous significant benefits to users," Tigner

The agreement also includes an additional contingent consideration of about $350m based on achievement of certain sales milestones The acquisition will give AMAG access to Lumara’s Makena, the

As part of the deal, Perrigo will receive an upfront payment in addition to multiple development-related milestone payments and royalties on any future sales derived from the portfolio.

Ligand earns a $550,000 milestone payment as a result of the approval. Ligand will sell Captisol to Merck for the product marketed in Europe under an existing commercial

The results, related to a secondary endpoint from the 250-patient trial, showed that 45% of patients treated with dabrafenib were still alive at two years compared to 32%

The early findings presented showed a confirmed overall response rate of 24 percent with KEYTRUDA as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI,

The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse.

The Janssen Research & Development, LLC ("Janssen")-sponsored registration study demonstrated a 19 percent reduction in risk of death in this study population (median OS, 34.7 vs 30.3 months,